Story perspectives

Senate Hearing Sparks Controversy Over Mifepristone Safety

1/15/2026

40 6

Center

Senators Scrutinize Mifepristone

The Senate Committee on Health, Education, Labor and Pensions held a hearing on mifepristone to examine its safety and regulatory framework.
Senator Bill Cassidy criticized the drug as dangerous.
The Supreme Court upheld access to mifepristone in 2024, while the Trump administration plans to review its approval.
Abortion medication regulations face ongoing tensions, as Senator Lindsey Graham opposes abortion pills.

Right

Senators Challenge Abortion Policies

Republican senators at a hearing on abortion pills criticized Dr. Nisha Verma for not answering whether men can get pregnant.
Sen. Josh Hawley said acknowledging biological realities is essential to avoid undermining science.
A press conference led by the Family Research Council urged the FDA to end Biden-era abortion drug policies.
Key figures included Sen. Lindsey Graham and state attorneys general, signaling a coordinated challenge to current abortion regulations.

History

Historical Context

The FDA approved mifepristone for medical abortions in 2000, following years of advocacy and opposition from anti-abortion groups. This approval intensified debates over reproductive rights, with organizations like the Family Research Council challenging its safety. By 2023, medication abortions accounted for 63% of all abortions in the U.S., reflecting ongoing societal divisions regarding abortion access and regulation.

1 of 3

Senators Scrutinize Mifepristone

The Senate Committee on Health, Education, Labor and Pensions held a hearing on mifepristone to examine its safety and regulatory framework.
Senator Bill Cassidy criticized the drug as dangerous.
The Supreme Court upheld access to mifepristone in 2024, while the Trump administration plans to review its approval.
Abortion medication regulations face ongoing tensions, as Senator Lindsey Graham opposes abortion pills.

1 / 3